S11 Ep48: FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer
OncLive® On Air - Un pódcast de OncLive® On Air
Dr Harding discusses the significance of the FDA approval of zanidatamab for patients with HER2-positive metastatic biliary tract cancer.
